PErsonalized TReatment for Endometrial Carcinoma

The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare: * Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup. * Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.

NCT Number	NCT05655260
Lead Sponsor	University of Helsinki Collaborators: Turku University Hospital, Tampere University Hospital, Kuopio University Hospital, Oulu University Hospital, Kymenlaakso Central Hospital Kotka Finland, Päijänne Tavastia Central Hospital, South Carelia Central Hospital
Conditions	Endometrial Adenocarcinoma
Enrollment	300 participants
Start Date	2022-02-08
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-12-06